MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss and
comprehensive loss
-$18,856K
(-39.25%↓ Y/Y)
INDOCINProducts
$3,446K
(-37.84%↓ Y/Y)
Sympazan
$2,580K
(18.40%↑ Y/Y)
SPRIXNasal Spray
$1,370K
(-13.78%↓ Y/Y)
Product Other
$1,009K
(-71.67%↓ Y/Y)
ROLVEDON
$493K
Net loss before
income taxes
-$18,811K
(-41.48%↓ Y/Y)
Income tax expense
$45K
(-81.63%↓ Y/Y)
Product
$8,898K
(-65.77%↓ Y/Y)
Product And Service
Other
$600K
Royalty
$435K
(-11.94%↓ Y/Y)
Loss from operations
-$18,470K
(-39.58%↓ Y/Y)
Total other expense
-$341K
(-441.27%↓ Y/Y)
Total revenues
$9,933K
(-62.50%↓ Y/Y)
Interest income
$469K
(-34.86%↓ Y/Y)
Total costs and
expenses
$28,403K
(-28.49%↓ Y/Y)
Interest expense
$775K
(1.31%↑ Y/Y)
Other loss
-$35K
(-94.44%↓ Y/Y)
Selling, general and
administrative expenses
$19,434K
(-11.56%↓ Y/Y)
Amortization of intangible
assets
$5,804K
(-37.14%↓ Y/Y)
Cost of sales
$2,711K
(-65.18%↓ Y/Y)
Research and development
expenses
$454K
(3.65%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Assertio Holdings, Inc. (ASRT)
Assertio Holdings, Inc. (ASRT)